ライフサイエンスコーパス: tenofovir disoproxil

1 creatinine increases than those given E/C/F/tenofovir disoproxil fumarate (0.08 vs 0.12 mg/dL; p<0.0

2 21 were in those assigned emtricitabine plus tenofovir disoproxil fumarate (0.48 cases per 100 person

3 r (400/100 mg) twice daily and emtricitabine/tenofovir disoproxil fumarate (200/300 mg) once daily.

4 mly assigned (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine

5 rticipants were given combination tablets of tenofovir disoproxil fumarate (300 mg) and emtricitabine

6 ivirine (25 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching pl

7 virenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching pl

8 ted with each additional year of exposure to tenofovir disoproxil fumarate (adjusted incidence rate r

9 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (combined ART).

10 placebo-controlled intensification trials of tenofovir disoproxil fumarate (DF) in treatment-experien

11 Tenofovir disoproxil fumarate (DF) is a once-daily nucle

12 Tenofovir disoproxil fumarate (DF) is highly effective f

13 omly assigned to receive either a regimen of tenofovir disoproxil fumarate (DF), emtricitabine, and e

14 group) or combination therapy with efavirenz-tenofovir disoproxil fumarate (DF)-emtricitabine once da

15 for HIV-1 infection: abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtricitabine plus ef

16 th placebo-controlled abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtricitabine.

17 of 4 animals received oral topical doses of tenofovir disoproxil fumarate (DF; equivalent to 0.037 m

18 8 versus 130 (93%) of 140 patients receiving tenofovir disoproxil fumarate (difference 1.8% [95% CI -

19 mide (E/C/F/tenofovir alafenamide) or 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxi

20 TC/TDF) with that of efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF).

21 acy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) with that

22 fumarate (TDF) and combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious

23 oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once

24 ated that combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure p

25 ophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) decreases the ri

26 posure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is a novel strat

27 In the United States, emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is a preferred n

28 e prophylaxis (PrEP) with emtricitabine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone red

29 in bone mineral density than those receiving tenofovir disoproxil fumarate (hip -0.29% [95% CI -0.55

30 ections, 31 occurred in individuals assigned tenofovir disoproxil fumarate (incidence 0.71 cases per

31 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (integrase inhibitor regim

32 o 100 mg, 67 to 200 mg, and 66 to 400 mg) or tenofovir disoproxil fumarate (n=101).

33 eive either tenofovir alafenamide (n=333) or tenofovir disoproxil fumarate (n=330).

34 nt with efavirenz and lamivudine plus either tenofovir disoproxil fumarate (n=55) or stavudine (n=45)

35 ir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate (protease inhibitor based

36 After adjustment, persons who had ever used tenofovir disoproxil fumarate (TDF) (1.40; 1.15-1.70) or

37 prophylaxis (PrEP) using the antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combinat

38 Tenofovir disoproxil fumarate (TDF) and adefovir dipivox

39 oviral preexposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF) and combination emtr

40 e randomly assigned to take a combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (F

41 ibitor (NNRTI) based FDC of rilpivirine plus tenofovir disoproxil fumarate (TDF) and emtricitabine (F

42 BACKGROUND & AIMS: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent antiviral

43 emtricitabine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumarate (TDF) as a 3-drug, single-

44 ected with HIV and HBV who were treated with tenofovir disoproxil fumarate (TDF) as part of highly ac

45 viral therapy currently receive some form of tenofovir disoproxil fumarate (TDF) as part of their HIV

46 phylaxis (PrEP) with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) can partially preven

47 chnology that delivers the tenofovir prodrug tenofovir disoproxil fumarate (TDF) continuously over 28

48 The approved tenofovir disoproxil fumarate (TDF) dose of 300 mg every

49 Tenofovir disoproxil fumarate (TDF) has been linked to r

50 cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) in a single tablet g

51 itis B e antigen positive patients receiving tenofovir disoproxil fumarate (TDF) in an open-label, lo

52 We examined the efficacy of tenofovir disoproxil fumarate (TDF) in blocking simian h

53 Despite widespread use of tenofovir disoproxil fumarate (TDF) in pregnant and brea

54 The efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother-t

55 ATV) in combination with emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in treatment-naive p

56 cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, s

57 Tenofovir disoproxil fumarate (TDF) is a nucleotide anal

58 Tenofovir disoproxil fumarate (TDF) is a nucleotide anal

59 Tenofovir disoproxil fumarate (TDF) is active against la

60 Tenofovir disoproxil fumarate (TDF) is an established nu

61 Tenofovir disoproxil fumarate (TDF) is associated with p

62 Tenofovir disoproxil fumarate (TDF) is commonly used in

63 Exposure to tenofovir disoproxil fumarate (TDF) may cause renal toxi

64 Tenofovir disoproxil fumarate (TDF) plays a pivotal role

65 Clinical studies of systemic tenofovir disoproxil fumarate (TDF) PrEP revealed reduce

66 from patients with rapid or slow response to tenofovir disoproxil fumarate (TDF) treatment, have been

67 NA >/= 9 log10 copies/mL, after 240 weeks of tenofovir disoproxil fumarate (TDF) treatment.

68 Although tenofovir disoproxil fumarate (TDF) use has increased as

69 differ among patients receiving LDV/SOF and tenofovir disoproxil fumarate (TDF) without a protease i

70 Some studies have shown that tenofovir disoproxil fumarate (TDF), a drug widely used

71 Once-daily oral tenofovir disoproxil fumarate (TDF), alone or combined w

72 lone, MVC plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.

73 MVC only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (contro

74 nd 7 had M184V/I (0.1%), despite high use of tenofovir disoproxil fumarate (TDF), emtricitabine, and

75 ug of tenofovir and a potential successor of tenofovir disoproxil fumarate (TDF), has been approved i

76 ed trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtr

77 Tenofovir disoproxil fumarate (TDF), the first nucleotid

78 l to demonstrate that a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent pro

79 ophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodr

80 It is unknown if tenofovir disoproxil fumarate (TDF), which is often cofo

81 We compared maraviroc (MVC)- to tenofovir disoproxil fumarate (TDF)-containing ART.

82 importance of renal and endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicit

83 We hypothesized that tenofovir disoproxil fumarate (TDF)-treated patients tak

84 ion antiretroviral therapy (cART) containing tenofovir disoproxil fumarate (TDF).

85 cluding the clinically approved formulation, tenofovir disoproxil fumarate (TDF).

86 ylactic efficacy of oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF).

87 men with symptomatic HSV-2 infection to oral tenofovir disoproxil fumarate (TDF)/placebo vaginal gel,

88 andomly assigned to groups given either oral tenofovir disoproxil fumarate (TDF, 300 mg) and placebo

89 Tenofovir disoproxil fumarate (tenofovir) has been assoc

90 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir) might be a saf

91 ed protease inhibitor and emtricitabine plus tenofovir disoproxil fumarate (tenofovir) regimen to cof

92 fenamide 0.01 mg/dL [95% CI 0.00 to 0.02] vs tenofovir disoproxil fumarate 0.02 mg/dL [0.00 to 0.04],

93 (tenofovir alafenamide 40 [14%] patients vs tenofovir disoproxil fumarate 14 [10%] patients), nasoph

94 , 200 mg, or 400 mg once a day or to receive tenofovir disoproxil fumarate 300 mg once a day; each al

95 oral doses of tenofovir alafenamide 25 mg or tenofovir disoproxil fumarate 300 mg, each with matching

96 ) ritonavir (RTV) or standard of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200

97 (PrEP) with Truvada (emtricitabine [FTC] and tenofovir disoproxil fumarate [TDF]) is a novel HIV prev

98 was not significantly different from that of tenofovir disoproxil fumarate alone (hazard ratio [HR] 0

99 ety and efficacy of daily oral emtricitabine-tenofovir disoproxil fumarate among HIV-seronegative men

100 Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC

101 seronegative men and women to receive either tenofovir disoproxil fumarate and emtricitabine (TDF-FTC

102 Daily, oral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC

103 Preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (Truvada

104 As pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine for the

105 f pre-exposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine in 2499

106 tonavir-boosted atazanavir plus coformulated tenofovir disoproxil fumarate and emtricitabine once a d

107 th darunavir/ritonavir and 2 nucleos(t)ides (tenofovir disoproxil fumarate and emtricitabine or abaca

108 g (one tablet) orally twice daily, each with tenofovir disoproxil fumarate and emtricitabine orally o

109 lled three-group phase 3 trial of daily oral tenofovir disoproxil fumarate and emtricitabine plus ten

110 atinine clearance and the number of doses of tenofovir disoproxil fumarate and emtricitabine taken pe

111 Patients started RAL in combination with tenofovir disoproxil fumarate and lamivudine after initi

112 BMS-986001 had similar efficacy to that of tenofovir disoproxil fumarate and was associated with a

113 ir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate and were followed up for H

114 ks, viral genotypes for nonresponders in the tenofovir disoproxil fumarate arm showed M184V or I/M/V

115 occurred in 50 (49%) of 102 subjects in the tenofovir disoproxil fumarate arm, compared with 5 (5%)

116 otocol was immediately amended to modify the tenofovir disoproxil fumarate arm.

117 e relative to combination emtricitabine plus tenofovir disoproxil fumarate as PrEP.

118 ir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate as PrEP.

119 bolite to target cells more efficiently than tenofovir disoproxil fumarate at a lower dose, thereby r

120 /ADAPT) of oral PrEP with emtricitabine plus tenofovir disoproxil fumarate at a research centre in Ca

121 Tenofovir disoproxil fumarate can cause renal and bone t

122 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compared with a boosted pr

123 a slight difference in HIV-1 protection with tenofovir disoproxil fumarate compared with emtricitabin

124 d trial of PrEP with oral emtricitabine plus tenofovir disoproxil fumarate compared with placebo in m

125 disoproxil fumarate; one patient assigned to tenofovir disoproxil fumarate did not receive the treatm

126 r alafenamide and 12 (4%) patients receiving tenofovir disoproxil fumarate experienced serious advers

127 men and had been on daily emtricitabine and tenofovir disoproxil fumarate for 8 months presented wit

128 ies per mL) on efavirenz, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months befo

129 s per mL) on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months befo

130 p<0.0001) and 93% for the emtricitabine plus tenofovir disoproxil fumarate group (0.07, 0.02-0.23; p<

131 amide group and in 444 (93%) assigned to the tenofovir disoproxil fumarate group (adjusted difference

132 enamide group compared with 307 (93%) in the tenofovir disoproxil fumarate group (difference 1.3%, 95

133 risk reduction in HIV-1 acquisition for the tenofovir disoproxil fumarate group (HR 0.15, 95% CI 0.0

134 per mL, compared with 88 (89%) of 99 in the tenofovir disoproxil fumarate group (modified intention-

135 lated to study treatment; one patient in the tenofovir disoproxil fumarate group died, but this was n

136 fovir alafenamide (2%) and three (1%) in the tenofovir disoproxil fumarate group discontinued due to

137 de group and 96 (33%) of 292 patients in the tenofovir disoproxil fumarate group had grade 3 or 4 lab

138 ruption and thrombocytopenia) and two in the tenofovir disoproxil fumarate group had study drug-relat

139 e group and 784 (90%) of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1

140 vir disoproxil fumarate-containing regimens (tenofovir disoproxil fumarate group) for 96 weeks.

141 e tenofovir alafenamide group and 314 to the tenofovir disoproxil fumarate group).

142 of 437 in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group.

143 e tenofovir alafenamide group and 477 to the tenofovir disoproxil fumarate group.

144 alafenamide group compared with those in the tenofovir disoproxil fumarate group.

145 e group compared with 37 (12%) of 314 in the tenofovir disoproxil fumarate group; none of these were

146 enofovir alafenamide and 294 (94%) of 313 on tenofovir disoproxil fumarate had maintained less than 5

147 alafenamide and nine (6%) patients receiving tenofovir disoproxil fumarate had serious adverse events

148 s given E/C/F/tenofovir alafenamide or E/C/F/tenofovir disoproxil fumarate had virological success.

149 Antiretroviral regimens containing tenofovir disoproxil fumarate have been associated with

150 daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtric

151 or to continuing rilpivirine, emtricitabine, tenofovir disoproxil fumarate in maintaining viral suppr

152 the efficacy and safety of BMS-986001 versus tenofovir disoproxil fumarate in treatment-naive patient

153 ily use of PrEP with oral emtricitabine plus tenofovir disoproxil fumarate in women.

154 Emtricitabine with tenofovir disoproxil fumarate is a standard-of-care nucl

155 However, tenofovir disoproxil fumarate is associated with renal a

156 re prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate is highly effective agains

157 Daily emtricitabine/tenofovir disoproxil fumarate is recommended as preexpos

158 ophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate is used to prevent the sex

159 mg of raltegravir twice daily and 300 mg of tenofovir disoproxil fumarate once daily as a backbone.

160 SVR12 among patients receiving either tenofovir disoproxil fumarate or abacavir as part of the

161 should be followed; adjustment should avoid tenofovir disoproxil fumarate or boosted protease inhibi

162 re offered rerandomisation in a 1:1 ratio to tenofovir disoproxil fumarate or emtricitabine plus teno

163 4410 (99.6%) of 4427 couples received tenofovir disoproxil fumarate or emtricitabine plus teno

164 oxil fumarate, but show that once-daily oral tenofovir disoproxil fumarate or emtricitabine plus teno

165 ts taking antiretroviral regimens containing tenofovir disoproxil fumarate or other nucleoside analog

166 exposure prophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fu

167 hylaxis (PrEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an

168 l tissue exposure by the third daily dose of tenofovir disoproxil fumarate plus emtricitabine.

169 open-label study of daily oral emtricitabine-tenofovir disoproxil fumarate PrEP among 50 HIV-uninfect

170 r disoproxil fumarate and emtricitabine plus tenofovir disoproxil fumarate PrEP in HIV-1 uninfected i

171 regimen and 402 (92%) of 437 assigned to the tenofovir disoproxil fumarate regimen (difference -2.0%,

172 eived one dose of study drug and were on the tenofovir disoproxil fumarate regimen before screening w

173 ir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate regimens both provide high

174 We assessed the efficacy of single-agent tenofovir disoproxil fumarate relative to combination em

175 n patients switching from emtricitabine with tenofovir disoproxil fumarate to emtricitabine with teno

176 responses were independent of emtricitabine/tenofovir disoproxil fumarate use.

177 randomized, open-label, multicenter study of tenofovir disoproxil fumarate versus efavirenz, both adm

178 amide-containing regimen from one containing tenofovir disoproxil fumarate was non-inferior for maint

179 afenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in mainta

180 prevention efficacy with emtricitabine plus tenofovir disoproxil fumarate was not significantly diff

181 erior to the 195 (67%) of patients receiving tenofovir disoproxil fumarate who had HBV DNA less than

182 either 25 mg tenofovir alafenamide or 300 mg tenofovir disoproxil fumarate with matching placebo.

183 amide and 36 [13%] of 288 patients receiving tenofovir disoproxil fumarate) and AST (20 [3%] of 577 p

184 ndividuals on cART (predominantly containing tenofovir disoproxil fumarate) were also more likely to

185 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matching placebo.

186 enamide vs 22 [8%] of 292 patients receiving tenofovir disoproxil fumarate), nasopharyngitis (56 [10%

187 /F/tenofovir alafenamide and 867 given E/C/F/tenofovir disoproxil fumarate).

188 amide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate).

189 men (both regimens include emtricitabine and tenofovir disoproxil fumarate).

190 (581 with tenofovir alafenamide and 292 with tenofovir disoproxil fumarate).

191 namide and 19 [7%] of 288 patients receiving tenofovir disoproxil fumarate).

192 lus combination emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate, 300 mg/d.

193 ir, either as a vaginal gel or as daily oral tenofovir disoproxil fumarate, alone or coformulated wit

194 ated metabolites of abacavir, emtricitabine, tenofovir disoproxil fumarate, amdoxovir, and zidovudine

195 ART-naive patients received RAL, tenofovir disoproxil fumarate, and emtricitabine for 72

196 ovir alafenamide was non-inferior to that of tenofovir disoproxil fumarate, and had improved bone and

197 n, tenofovir alafenamide was non-inferior to tenofovir disoproxil fumarate, and had improved bone and

198 mbination of lopinavir/ritonavir, efavirenz, tenofovir disoproxil fumarate, and lamivudine and compar

199 l density than a standard regimen containing tenofovir disoproxil fumarate, and might be a treatment

200 il fumarate compared with emtricitabine plus tenofovir disoproxil fumarate, but show that once-daily

201 wer among infants exposed from conception to tenofovir disoproxil fumarate, emtricitabine, and efavir

202 Newer agents including tenofovir disoproxil fumarate, entecavir, and telbivudin

203 Compared with tenofovir disoproxil fumarate, individuals in the BMS-98

204 of 99 and one (1%) of 99 patients receiving tenofovir disoproxil fumarate, respectively.

205 sease associated with cumulative exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazana

206 e increased for up to 6 years of exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazana

207 iled macaques were treated with a regimen of tenofovir disoproxil fumarate, saquinavir, atazanavir, a

208 Tenofovir disoproxil fumarate, the most recently approve

209 r plasma concentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone a

210 cells more efficiently at a lower dose than tenofovir disoproxil fumarate, thereby reducing systemic

211 ovir regimens, each for 6 weeks (oral 300 mg tenofovir disoproxil fumarate, vaginal 1% tenofovir gel

212 e 200 mg emtricitabine with 200 mg or 300 mg tenofovir disoproxil fumarate, while remaining on the sa

213 ofovir alafenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, with 800 (92%) of 866 pat

214 tenofovir alafenamide was as efficacious as tenofovir disoproxil fumarate, with reduced bone and ren

215 lso extend to HIV-negative individuals using tenofovir disoproxil fumarate-based pre-exposure prophyl

216 Nearly all (97.6%) patients received tenofovir disoproxil fumarate-containing ART, in line wi

217 ) or to carry on taking one of four previous tenofovir disoproxil fumarate-containing regimens (tenof

218 min or greater, and were taking one of four tenofovir disoproxil fumarate-containing regimens for at

219 improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens.

220 aive participants were randomized to receive tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) pl

221 despite consistent use of emtricitabine and tenofovir disoproxil fumarate.

222 improved renal and bone safety compared with tenofovir disoproxil fumarate.

223 in patients switched from emtricitabine with tenofovir disoproxil fumarate.

224 n with initiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate.

225 non-inferiority of tenofovir alafenamide to tenofovir disoproxil fumarate.

226 osted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate.

227 remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate.

228 ir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate.

229 versus in those remaining on one containing tenofovir disoproxil fumarate.

230 n coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

231 argin of tenofovir alafenamide compared with tenofovir disoproxil fumarate.

232 The tenofovir disoproxil fumarate/abacavir/lamivudine regime

233 This study estimated the number of daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) do

234 phylaxis (PrEP) interventions worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) fo

235 ment-naive individuals randomized equally to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pl

236 Daily tenofovir disoproxil fumarate/emtricitabine is recommend

237 re associated with suboptimal adherence, and tenofovir disoproxil fumarate/emtricitabine was associat

238 se inhibitors (NRTIs; abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabine) and a third

239 to tenofovir alafenamide and 141 assigned to tenofovir disoproxil fumarate; one patient assigned to t

240 TV+DDI+FTC), or efavirenz plus emtricitabine-tenofovir-disoproxil fumarate (DF) (EFV+FTC-TDF).

241 articipants were randomized 1:1:1 to receive tenofovir-disoproxil fumarate (DF) plus emtricitabine, a

242 idanosine-EC, n = 293), and C (emtricitabine-tenofovir-disoproxil fumarate plus efavirenz, n = 278) a

243 tor-selected regimen of background N(t)RTIs (tenofovir-disoproxil-fumarate plus emtricitabine, zidovu

244 ng fixed-dose combination emtricitabine with tenofovir disoproxil fumartate from 78 sites in North Am